Trial Profile
A Pilot Clinical Trial Assessing the Safety and Feasibility of Intramuscular Administration of the TA-CIN Vaccine as Adjuvant Therapy for Patients With History of HPV16 Associated Cervical Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 02 Aug 2023
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine (Primary)
- Indications Cervical cancer
- Focus Adverse reactions
- 27 Jul 2023 Planned End Date changed from 1 Jan 2024 to 31 Dec 2024.
- 27 Jul 2023 Planned primary completion date changed from 1 Dec 2023 to 31 Mar 2024.
- 22 Jul 2022 Planned primary completion date changed from 1 Jun 2022 to 1 Dec 2023.